- PROFESSOR Medicine, Gastroenterology
American Board of Internal Medicine
* SUNY at Stony Brook School of Medicine *
* Albert Einstein College of Medicine *
- Dr. Albert D. Min is an expert on management of patients with chronic viral hepatitis, involved in numerous clinical trials of antiviral therapy both in hepatitis B and C, and has presented his research data at various national meetings. He is also involved extensively in managing and evaluating patients with end-stage liver disease for liver transplantation. In addition, he is interested in early detection of possible primary liver cancer and its outcome in patients with underlying chronic liver disease. As the Director of the Liver Clinic at Mount Sinai he is closely involved in the teaching of liver and gastroenterology fellows on consultative hepatology practice.
Senior Research Fellow Award
American Gastroenterological Association
Phi Beta Kappa
Viral Hepatitis, Hepatitis B, Hepatitis C, Cirrhosis, Hepatocellular carcinoma, Liver Transplantation
Min A, Saxena R, Thung SN, Atillasoy EO, Wolf DC, Sauter B, Schwartz ME, Bodenheimer HC Jr.. Outcome of hepatitis C patients undergoing liver transplant with and without hepatocellular carcinoma. Am J Gastroenterol 1998; 93: 2148-2153.
Ye MA, Suriawinata A, Black C, Min A, Strauche J, Thung SN. Primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type in a patient with primary biliary cirrhosis. Arch Pathol Lab Med 2000; 124: 604-608.
Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min A. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Amer J Gastro 2000; 95: 1535-1538.
Schiano T, Bodian C, Schwartz ME, Glajchen N, Min A. Accuracy and significance of CT scan assessment of hepatic volume in patients undergoing liver transplantation . Transplantation 2000; 69: 545-550.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Min during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Bristol-Myers Squibb; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Bristol-Myers Squibb; Gilead Sciences, Inc.; Kadmon Corporation, LLC; Salix Pharmaceuticals, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.